68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial

Conclusion: We confirmed an association of 68Ga-FAPI PET SUVmax and histopathologic FAP expression in pancreatic cancer patients. Additionally, we found high detection rate and diagnostic accuracy, superior to those of 18F-FDG PET/CT. 68Ga-FAPI might become a powerful diagnostic tool for pancreatic cancer work-up.

Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Kessler, L., Hirmas, N., Pabst, K. M., Hamacher, R., Ferdinandus, J., Schaarschmidt, B. M., Milosevic, A., Nader, M., Umutlu, L., Uhl, W., Reinacher-Schick, A., Lugnier, C., Witte, D., Niedergethmann, M., Herrmann, K., Fendler, W. P., Siveke, J. T. Tags: Clinical Investigations Source Type: research